IP Verse

Identification Of Patients In Need Of Pd-L1 Inhibitor Cotherapy - EP2926142

The patent EP2926142 was granted to F Hoffmann LA Roche on Jul 6, 2022. The application was originally filed on Nov 29, 2013 under application number EP13814848A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2926142

F HOFFMANN LA ROCHE
Application Number
EP13814848A
Filing Date
Nov 29, 2013
Status
Patent Maintained As Amended
Jun 3, 2022
Grant Date
Jul 6, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BAYERAug 7, 2019MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBADMISSIBLE

Patent Citations (215) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONDE3218121
DESCRIPTIONEP0036676
DESCRIPTIONEP0052322
DESCRIPTIONEP0058481
DESCRIPTIONEP0088046
DESCRIPTIONEP0102324
DESCRIPTIONEP0133988
DESCRIPTIONEP0142641
DESCRIPTIONEP0143949
DESCRIPTIONEP0412116
DESCRIPTIONEP0444181
DESCRIPTIONEP0494135
DESCRIPTIONEP0502812
DESCRIPTIONEP0554441
DESCRIPTIONEP0599274
DESCRIPTIONEP0616812
DESCRIPTIONEP0656367
DESCRIPTIONEP0711565
DESCRIPTIONEP1006194
DESCRIPTIONEP1357132
DESCRIPTIONJPS58118008
DESCRIPTIONUS2002031515
DESCRIPTIONUS2002051785
DESCRIPTIONUS2002064785
DESCRIPTIONUS2002076408
DESCRIPTIONUS2002076695
DESCRIPTIONUS2002090662
DESCRIPTIONUS2002141993
DESCRIPTIONUS2002142328
DESCRIPTIONUS2002155527
DESCRIPTIONUS2002192211
DESCRIPTIONUS2002192652
DESCRIPTIONUS2003022918
DESCRIPTIONUS2003059790
DESCRIPTIONUS2003068318
DESCRIPTIONUS2003086924
DESCRIPTIONUS2003103973
DESCRIPTIONUS2003108545
DESCRIPTIONUS2003134344
DESCRIPTIONUS2003144252
DESCRIPTIONUS2003147884
DESCRIPTIONUS2003152572
DESCRIPTIONUS2003152987
DESCRIPTIONUS2003157097
DESCRIPTIONUS2003165840
DESCRIPTIONUS2003170234
DESCRIPTIONUS2003175845
DESCRIPTIONUS2003190689
DESCRIPTIONUS2003202973
DESCRIPTIONUS2003211530
DESCRIPTIONUS2003228663
DESCRIPTIONUS2004013297
DESCRIPTIONUS2004013667
DESCRIPTIONUS2004024815
DESCRIPTIONUS2004082047
DESCRIPTIONUS2004106161
DESCRIPTIONUS2004138160
DESCRIPTIONUS2004209290
DESCRIPTIONUS2004236078
DESCRIPTIONUS2004258685
DESCRIPTIONUS2005002928
DESCRIPTIONUS2006018899
DESCRIPTIONUS3773919
DESCRIPTIONUS4485045
DESCRIPTIONUS4544545
DESCRIPTIONUS4935341
DESCRIPTIONUS4968603
DESCRIPTIONUS5183884
DESCRIPTIONUS5288477
DESCRIPTIONUS5401638
DESCRIPTIONUS5480968
DESCRIPTIONUS5514554
DESCRIPTIONUS5571894
DESCRIPTIONUS5587458
DESCRIPTIONUS5604107
DESCRIPTIONUS5641869
DESCRIPTIONUS5648237
DESCRIPTIONUS5677171
DESCRIPTIONUS5705157
DESCRIPTIONUS5720937
DESCRIPTIONUS5720954
DESCRIPTIONUS5725856
DESCRIPTIONUS5747261
DESCRIPTIONUS5770195
DESCRIPTIONUS5772997
DESCRIPTIONUS5783186
DESCRIPTIONUS5783404
DESCRIPTIONUS5804396
DESCRIPTIONUS5821337
DESCRIPTIONUS5824311
DESCRIPTIONUS5837243
DESCRIPTIONUS5846749
DESCRIPTIONUS5856089
DESCRIPTIONUS5877305
DESCRIPTIONUS5910486
DESCRIPTIONUS5922845
DESCRIPTIONUS5925519
DESCRIPTIONUS5939531
DESCRIPTIONUS5977322
DESCRIPTIONUS5985553
DESCRIPTIONUS5994071
DESCRIPTIONUS6015567
DESCRIPTIONUS6028059
DESCRIPTIONUS6054297
DESCRIPTIONUS6123939
DESCRIPTIONUS6127526
DESCRIPTIONUS6165464
DESCRIPTIONUS6214388
DESCRIPTIONUS6267958
DESCRIPTIONUS6270765
DESCRIPTIONUS6333169
DESCRIPTIONUS6333348
DESCRIPTIONUS6333398
DESCRIPTIONUS6339142
DESCRIPTIONUS6358682
DESCRIPTIONUS6387371
DESCRIPTIONUS6395272
DESCRIPTIONUS6399063
DESCRIPTIONUS6403630
DESCRIPTIONUS6407213
DESCRIPTIONUS6417335
DESCRIPTIONUS6458356
DESCRIPTIONUS6489447
DESCRIPTIONUS6512097
DESCRIPTIONUS6573043
DESCRIPTIONUS6582919
DESCRIPTIONUS6602670
DESCRIPTIONUS6627196
DESCRIPTIONUS6632979
DESCRIPTIONUS6685940
DESCRIPTIONUS6719971
DESCRIPTIONUS6767541
DESCRIPTIONUS6797814
DESCRIPTIONUS6800738
DESCRIPTIONUS6821515
DESCRIPTIONWO0061145
DESCRIPTIONWO0061185
DESCRIPTIONWO0069460
DESCRIPTIONWO0078347
DESCRIPTIONWO0100238
DESCRIPTIONWO0100244
DESCRIPTIONWO0100245
DESCRIPTIONWO0105425
DESCRIPTIONWO0109187
DESCRIPTIONWO0115730
DESCRIPTIONWO0120033
DESCRIPTIONWO0121192
DESCRIPTIONWO0132155
DESCRIPTIONWO0153354
DESCRIPTIONWO0156604
DESCRIPTIONWO0164246
DESCRIPTIONWO0176586
DESCRIPTIONWO0176630
DESCRIPTIONWO0187334
DESCRIPTIONWO0187336
DESCRIPTIONWO0189566
DESCRIPTIONWO02055106
DESCRIPTIONWO0205791
DESCRIPTIONWO02070008
DESCRIPTIONWO02087619
DESCRIPTIONWO02089842
DESCRIPTIONWO0209754
DESCRIPTIONWO0211677
DESCRIPTIONWO0244413
DESCRIPTIONWO0245653
DESCRIPTIONWO03006509
DESCRIPTIONWO03012072
DESCRIPTIONWO03028638
DESCRIPTIONWO03041736
DESCRIPTIONWO03086467
DESCRIPTIONWO03087131
DESCRIPTIONWO2004000094
DESCRIPTIONWO2004008099
DESCRIPTIONWO2004024866
DESCRIPTIONWO2004048525
DESCRIPTIONWO2004053497
DESCRIPTIONWO2004063709
DESCRIPTIONWO2005117553
DESCRIPTIONWO2006133396
DESCRIPTIONWO2009089149
DESCRIPTIONWO2010077634
DESCRIPTIONWO2011066342
DESCRIPTIONWO2011109789
DESCRIPTIONWO8707646
DESCRIPTIONWO8910412
DESCRIPTIONWO9102062
DESCRIPTIONWO9105264
DESCRIPTIONWO9303741
DESCRIPTIONWO9312220
DESCRIPTIONWO9316185
DESCRIPTIONWO9321232
DESCRIPTIONWO9321319
DESCRIPTIONWO9400136
DESCRIPTIONWO9422478
DESCRIPTIONWO9607321
DESCRIPTIONWO9616673
DESCRIPTIONWO9640789
DESCRIPTIONWO9700271
DESCRIPTIONWO9720858
DESCRIPTIONWO9738731
DESCRIPTIONWO9802463
DESCRIPTIONWO9817797
DESCRIPTIONWO9818489
DESCRIPTIONWO9833914
DESCRIPTIONWO9845479
DESCRIPTIONWO9931140
DESCRIPTIONWO9948527
DESCRIPTIONWO9955367
INTERNATIONAL-SEARCH-REPORTWO2006133396
INTERNATIONAL-SEARCH-REPORTWO2009089149
INTERNATIONAL-SEARCH-REPORTWO2010077634
INTERNATIONAL-SEARCH-REPORTWO2011066342
INTERNATIONAL-SEARCH-REPORTWO2011109789
OPPOSITIONWO2010077634
OPPOSITIONWO2011066389

Non-Patent Literature (NPL) Citations (21) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "Breast cancer", Wikipedia, (20121129), pages 1 - 19, URL: https://en.wikipedia.org//index.php?title=Brea st_ cancer&olditl?525497239, XP055627200-
OPPOSITION- ESTEVA F et al., "CD 40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer", Breast Cancer Research, (20071217), vol. 9, no. 6, page R87, XP021041278-
OPPOSITION- "Estrogen receptor", Wikipedia, (20121015), URL: https://en.wikipedia,org/w/iiidex-php7title=Estro gen_receptor&oldid=517956676, XP055627212-
OPPOSITION- "HER2/neu", Wikipedia, (20121026), pages 1 - 8, URL: https://en.wikipedia.org/w/index,php?title=HER 2/neu&oldid=519951136, XP055627171-
OPPOSITION- "Leitlinienprogramm Onkologie", Interdisziplinare S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms Langversion 3.0, Aktualisierung 2012, (20120700), pages 1 - 362-
OPPOSITION- "Leitlinienprogramm Onkologie", Interdisziplinare S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms Langversion 3.0, Aktualisierung 2012, (20120700), pages 1 - 362, XP055627187-
OPPOSITION- MITCHELL, MS, "Combinations of anticancer drugs and immunotherapy", Cancer Immunology, Immunotherapy, (20030826), vol. 52, no. 11, pages 686 - 692, XP002993102-
OPPOSITION- MOLINA MA et al., "a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells", Cancer Res., (20010615), vol. 61, no. 12, pages 4744 - 9, XP002408598-
OPPOSITION- "PD-L1", Wikipedia article, (20110922), URL: https:/ /en.wikipedia.org/w /index.php?title=PD- Ll&oldid=451891615, XP055627167-
OPPOSITION- "Programmed cell death protein 1", Wikipedia, (20121023), URL: https://en.wikipedia.org/w/index.php?title=Prog rammed_ cell _death_protein_1&oldid=51930 54 74, XP055627213-
OPPOSITION- Stagg et al., "Supporting Information Anti-BrbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti- CD 137 mAb therapy", Proc Natl Acad Sci U S A., (20110411), vol. 108, no. 17, pages 1 - 5, XP055627238-
OPPOSITION- "Targeted Therapy", Wikipedia, (20121112), URL: https://en.wikipedia.org/w/index.php?title=Targ eted_therapy&oldid=522675520, XP055627202-
OPPOSITION- "Trastuzumab", Wikipedia, (20121127), URL: https://en,wikipedia.org/w/index.php?title=Trast uzumab&oMtd=525138397, XP055627209-
OPPOSITION- UNTCH M et al., "Neoadjuvant treatment with trastuzumab in RER2-positive breast cancer: results from the GeparQtiattro study", J Clin Oncol, (20100320), vol. 28, no. 12, pages 2024 - 2031, XP055627248-
OPPOSITION- ZHANG P et al., "Chemopreventive agents induce programmed death-1-ligand 1 (PD- L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis", Molecular Immunology, (20071024), vol. 45, no. 5, doi:10.1016/j.molimm.2007.08.013, pages 1470 - 1476, XP022402180
OPPOSITION- DONG H et al., "Tumor-associated B7-H1 promotes T- cell apoptosis: a potential mechanism of immune evasion", Nature medicine, (20020624), vol. 8, no. 8, doi:10.1038/nm730, pages 793 - 800, XP002397368
OPPOSITION- CURIEL TJ et al., "Blockade of B7-Hl improves myeloid dendritic cell - mediated antitumor immunity", Nature medicine, (20030421), vol. 9, no. 5, doi:10.1038/nm863, pages 562 - 567, XP002311470
OPPOSITION- VANNEMAN M et al., "Combining immunotherapy and targeted therapies in cancer treatment", Nat Rev Cancer., (20120322), vol. 12, no. 4, doi:10.1038/nrc3237, pages 237 - 25, XP055045378
OPPOSITION- WEBER, J., "Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer - Preclinical Background: CTLA-4 and PD-1 Blockade", Seminars in Oncology, vol. 37, no. 5, doi:10.1053/j.seminoncol.2010.09.005, ISSN 0093-7754, (20101110), pages 430 - 439, URL: https://doi.org/10.1053/j.seminoncol. 2010.09.00 5, XP009177527
OPPOSITION- STAGG J et al., "Anti-BrbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti- CD 137 mAb therapy", Proc Natl Acad Sci U S A., (20110411), vol. 108, no. 17, pages 7142 - 7147, XP002770427
OPPOSITION- GHEBEH H et al., "The B7-Hl (PD-L1) T lymphocyte- inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors", Neoplasia, (20060300), vol. 8, no. 3, doi:10.1593/neo.05733, pages 190 - 8, XP008091677

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents